In HF with LVEF ≤ 42.5%, sacubitril–valsartan vs RAS inhibitors reduced a composite of CV death or HF hospitalization - KIVIRID

In HF with LVEF ≤ 42.5%, sacubitril–valsartan vs RAS inhibitors reduced a composite of CV death or HF hospitalization

Authors: Sounok Sen, L. Kristin Newby

Published: 2020-06-15

DOI: 10.7326/acpj202006160-065

Source: Full article

Abstract

No abstract found.